0
No votes yet
ONS Guidelines Article

Supplementary Material for ONS Guidelines™ Management of Opioid-Induced and Treatment-Related Constipation: Systematic Review and Meta-Analysis

ONF 2020, 1-51 DOI:

Table of Contents

  1. PICO questions
  2. Search strategies
  3. Evidence risk of bias figure
  4. Evidence Profiles
  • Bowel regimen and lifestyle education vs. lifestyle education for opioid-induced constipation
  • Osmotic PEG and lifestyle education vs. lifestyle education for opioid-induced constipation
  • Methylnaltrexone (subcutaneous or oral) and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Naldemedine (0.2 mg) and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Naloxegol and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Lubiprostone and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Linaclotide and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Prucalopride and bowel regimen vs. bowel regimen for opioid-induced constipation
  • Osmotic or stimulant laxatives and lifestyle education vs. lifestyle education for non-opioid-related constipation
  • Acupuncture and lifestyle education vs. lifestyle education for non-opioid-related constipation
  • Electroacupuncture and lifestyle education vs. lifestyle education for non-opioid-related constipation
  1. Forest plots
  • Laxatives—Bowel movement frequency
  • Laxatives—Adverse events leading to treatment discontinuation
  • Naldemedine—Spontaneous Bowel Movements (SBMs)
  • Naldemedine—Adverse events leading to treatment discontinuation
  • Acupuncture—Bristol Stool Form Scale
  • Acupuncture—Adverse events
  • Acupuncture—Development of constipation
  1. Characteristics of included studies